TITLE

Resistance to lamivudine therapy: is there more than meets the eye

AUTHOR(S)
Dusheiko, G.; Bertoletti, A.
PUB. DATE
January 2005
SOURCE
Gut;Jan2005, Vol. 54 Issue 1, p9
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article reports that the goals of treatment of hepatitis B are to prevent progression of the disease or to slow the disease process. Hepatitis B virus (HBV) is a DNA virus which integrates into the host genome. Thus it is difficult to eradicate viraemia. However, it is possible, albeit in a minority, to reduce levels of viraemia to relatively low threshold levels after finite courses of treatment with either interferon alpha or nucleoside analogues, and to lessen the induced necroinflammatory and immune response. Two major forms of active chronic hepatitis B are recognised: wild-type or hepatitis Be antigen positive chronic HBV infection and anti-HBe positive or precore mutant disease. The latter disease is caused by variants of HBV that contain nucleotide substitutions in the core promoter/precore regions of the viral genome.
ACCESSION #
16163218

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics